Biomunex Pharmaceuticals, a biopharmaceutical company that develops immunotherapies through the discovery and development of bi- and multi-specific antibodies in cancer treatment, has appointed Dr. Simon Plyte as chief scientific officer (CSO) and as a member of its scientific advisory board.   Plyte brings a wealth of knowledge and experience, spanning over two decades in R&D at the senior management level, within the pharmaceutical and biotechnology industry. He has a proven track record...